<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71562</article-id><article-id pub-id-type="doi">10.7554/eLife.71562</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Risk of heart disease following treatment for breast cancer: results from a population-based cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-45507"><name><surname>Yang</surname><given-names>Haomin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2252-2606</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-62843"><name><surname>Bhoo Pathy</surname><given-names>Nirmala</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0568-8863</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-244783"><name><surname>Brand</surname><given-names>Judith S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244784"><name><surname>Hedayati</surname><given-names>Elham</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-180543"><name><surname>Grassmann</surname><given-names>Felix</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1390-7528</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244785"><name><surname>Zeng</surname><given-names>Erwei</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244786"><name><surname>Bergh</surname><given-names>Jonas</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-244787"><name><surname>Bian</surname><given-names>Weiwei</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244788"><name><surname>Ludvigsson</surname><given-names>Jonas F</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-53228"><name><surname>Hall</surname><given-names>Per</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5640-9126</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-34316"><name><surname>Czene</surname><given-names>Kamila</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Epidemiology and Health Statistics</institution>, <institution>Fujian Medical University</institution>, <addr-line><named-content content-type="city">Fuzhou</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">Department of Social and Preventive Medicine</institution>, <institution>University of Malaya</institution>, <addr-line><named-content content-type="city">Kuala Lumpur</named-content></addr-line>, <country>Malaysia</country></aff><aff id="aff3"><institution content-type="dept">School of Medical Sciences</institution>, <institution>Örebro University</institution>, <addr-line><named-content content-type="city">Örebro</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff4"><institution content-type="dept">Department of Oncology-Pathology</institution>, <institution>Karolinska Institutet</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff5"><institution content-type="dept">Department of Medical Epidemiology and Biostatistics</institution>, <institution>Karolinska Institutet</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-216139"><name><surname>Arap</surname><given-names>Wadih</given-names></name><role>Reviewing editor</role><aff><institution>Rutgers Cancer Institute of New Jersey</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>haomin.yang@ki.se</email> (HY);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>03</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e71562</elocation-id><history><date date-type="received"><day>23</day><month>06</month><year>2021</year></date><date date-type="accepted"><day>08</day><month>03</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Yang et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Yang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71562-v1.pdf"/><abstract><p><bold>Background:</bold> There is a rising concern about treatment-associated cardiotoxicities in breast cancer patients. This study aimed to determine the time- and treatment-specific incidence of arrhythmia, heart failure and ischemic heart disease in women diagnosed with breast cancer.</p><p><bold>Methods:</bold> A register-based matched cohort study was conducted including 8015 breast cancer patients diagnosed from 2001-2008 in the Stockholm-Gotland region and followed-up until 2017. Time-dependent risks of arrhythmia, heart failure and ischemic heart disease in breast cancer patients were assessed using flexible parametric models as compared to matched controls from general population. Treatment-specific effects were estimated in breast cancer patients using Cox model.</p><p><bold>Results:</bold> Time-dependent analyses revealed long-term increased risks of arrhythmia and heart failure following breast cancer diagnosis. Hazard ratios (HRs) within the first year of diagnosis were 2.14 (95% CI = 1.63-2.81) for arrhythmia and 2.71 (95% CI = 1.70-4.33) for heart failure. HR more than 10 years following diagnosis was 1.42 (95% CI = 1.21-1.67) for arrhythmia and 1.28 (95% CI = 1.03-1.59) for heart failure. The risk for ischemic heart disease was significantly increased only during the first year after diagnosis (HR=1.45, 95% CI = 1.03-2.04). Trastuzumab and anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease was identified following loco-regional radiotherapy.</p><p><bold>Conclusions:</bold> Administration of systemic adjuvant therapies appears to be associated with increased risks of heart disease. The risk estimates observed in this study may aid adjuvant therapy decision-making and patient counseling in oncology practices.</p><p><bold>Funding:</bold> This work was supported by the Swedish Research Council [grant no: 2018-02547]; Swedish Cancer Society [grant no: CAN-19-0266] and FORTE [grant no: 2016-00081].</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003392</institution-id><institution>Natural Science Foundation of Fujian Province</institution></institution-wrap></funding-source><award-id>2021J01721</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Haomin</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>China Scholarship council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Bian</surname><given-names>Weiwei</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Startup Fund for High-level Talents of Fujian Medical University</institution></institution-wrap></funding-source><award-id>XRCZX2020007</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Haomin</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Startup Fund for Scientific Research, Fujian Medical University</institution></institution-wrap></funding-source><award-id>2019QH1002</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Haomin</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Laboratory Construction Program of Fujian Medical University</institution></institution-wrap></funding-source><award-id>1100160208</award-id><principal-award-recipient><name><surname>Yang</surname><given-names>Haomin</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>2018-02547</award-id><principal-award-recipient><name><surname>Czene</surname><given-names>Kamila</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012538</institution-id><institution>Swedish Cancer Foundation</institution></institution-wrap></funding-source><award-id>CAN-19-0266</award-id><principal-award-recipient><name><surname>Czene</surname><given-names>Kamila</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006636</institution-id><institution>Forskningsrådet om Hälsa, Arbetsliv och Välfärd</institution></institution-wrap></funding-source><award-id>2016-00081</award-id><principal-award-recipient><name><surname>Czene</surname><given-names>Kamila</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution>University of Malaya Impact-Oriented Interdisciplinary Research Grant Programme</institution></institution-wrap></funding-source><award-id>IIRG006C-19HWB</award-id><principal-award-recipient><name><surname>Bhoo Pathy</surname><given-names>Nirmala</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>China scholarship council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zeng</surname><given-names>Erwei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Nirmala Bhoo Pathy, received educational grants to their institution from Novartis, Pfizer, AIA Bhd and Pharmaceutical Association of Malaysia.Has received speaker's fees from Novartis, Pfizer and Roche, and received travel support from Roche and Pharmaceutical Association of Malaysia to attend conferences in 2018 and 2019. Has served on the advisory board of Pfizer Asia Pacific, Malaysia (2017/18 year), and been a committee member for Together Against Cancer (NGO) (2018 and 2019). Roche Diagnostics also provided Nirmala Bhoo-Pathy with research material, namely COVID-19 total antibody kits. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Jonas Bergh, research was supported by payments from Amgen, AstraZeneca, Bayer, Merck, Roche and Sanofi-Aventis to their institution, along with payments from non-profit organisations (Swedish Cancer Society and Knut Alice Wallenberg) and the Swedish Research Council. Also gave lectures to Astra Zeneca and Roche (no personal payment was received for these). Is a scientific advisor to The Medical product agency and to EMA, and is a representative of Swedish Breast Cancer Group. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>Jonas F Ludvigsson, coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). This study has received funding from Janssen corporation. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/254-31/4). In accordance with their decision, it was not necessary to obtain informed consent from participants involved in the study. All individuals' information was anonymized and de-identified prior to analysis.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. According to Swedish law and GDPR, the authors are not able to make the dataset publicly available. Any researchers (including international researchers) interested in obtaining the data can do so by the following steps: 1) apply for ethical approval from their local ethical review boards; 2) contact the Swedish National Board of Health and Welfare and/or Statistics Sweden with the ethical approval and make a formal application of use of register data.</p></sec><supplementary-material><ext-link xlink:href="elife-71562-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>